Clinical and Experimental Nephrology

, Volume 17, Issue 5, pp 743–749

Excess fluid distribution affects tacrolimus absorption in peritoneal dialysis patients

  • Tadashi Sofue
  • Masashi Inui
  • Hideyasu Kiyomoto
  • Kumiko Moriwaki
  • Taiga Hara
  • Kazunori Yamaguchi
  • Noriyasu Fukuoka
  • Kazuko Banno
  • Akira Nishiyama
  • Yoshiyuki Kakehi
  • Masakazu Kohno
Original Article

Abstract

Background

Excess fluid distribution is a common disorder in peritoneal dialysis (PD) patients. Tacrolimus malabsorption may also occur in PD patients, and may lead to acute allograft rejection after transplantation. The purpose of this study was to evaluate the relationship between tacrolimus pharmacokinetics and excess fluid distribution according to pre-transplant dialysis modality.

Methods

We retrospectively analyzed 41 adult living-donor kidney transplantations, including nine PD patients and 32 hemodialysis (HD) patients. We examined tacrolimus pharmacokinetics in the peri-operative period and determined the association between the tacrolimus absorption rate and body weight reduction. The absorption efficacy of tacrolimus was evaluated as the dose-normalized tacrolimus absorption rate. Tacrolimus concentrations in PD effluent were measured by high-performance liquid chromatography.

Results

The tacrolimus absorption rate on the day before kidney transplantation tended to be lower in PD patients than in HD patients; however, the rate improved after kidney transplantation and was similar in both groups of patients. The peak tacrolimus concentration time was later in PD patients than in HD patients. The body weight reduction after kidney transplantation was greater in PD patients than in HD patients, and was significantly associated with the change in tacrolimus absorption rate (p = 0.04, r = 0.32). Only 0.002 % of the oral tacrolimus dose was removed by PD itself.

Conclusion

Excess fluid distribution in PD patients appears to contribute to tacrolimus malabsorption rather than PD itself. We should consider the risk of tacrolimus malabsorption in patients with possible excess fluid distribution, particularly in PD patients.

Keywords

Peritoneal dialysis Excess fluid distribution Tacrolimus pharmacokinetics Living-donor kidney transplantation 

References

  1. 1.
    Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Edwards EB, Bennett LE, Cecka JM. Effect of HLA matching on the relative risk of mortality for kidney recipients: a comparison of the mortality risk after transplant to the mortality risk of remaining on the waiting list. Transplantation. 1997;64:1274–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Burra P, De Bona M. Quality of life following organ transplantation. Transpl Int. 2007;20:397–409.PubMedCrossRefGoogle Scholar
  4. 4.
    Snyder JJ, Kasiske BL, Gilbertson DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int. 2002;62:1423–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Konings CJ, Kooman JP, Schonck M, et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int. 2002;22:477–87.PubMedGoogle Scholar
  6. 6.
    John B, Tan BK, Dainty S, Spanel P, Smith D, Davies SJ. Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol. 2010;5:1463–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Plum J, Schoenicke G, Kleophas W, et al. Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant. 2001;16:2378–85.PubMedCrossRefGoogle Scholar
  8. 8.
    Van Biesen W, Williams JD, Covic AC, et al. Fluid status in peritoneal dialysis patients: the European Body Composition Monitoring (EuroBCM) study cohort. PLoS One. 2011;6:e17148.PubMedCrossRefGoogle Scholar
  9. 9.
    Crone CC, Gabriel GM. Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations. Clin Pharmacokinet. 2004;43:361–94.PubMedCrossRefGoogle Scholar
  10. 10.
    Morrissey PE, Gohh R, Shaffer D, et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation. 1997;63:845–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Coto E, Tavira B. Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation. 2009;88:S62–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Mourad M, Wallemacq P, De Meyer M, et al. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. Transplantation. 2008;85:S19–24.PubMedCrossRefGoogle Scholar
  13. 13.
    Anglicheau D, Verstuyft C, Laurent-Puig P, et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J Am Soc Nephrol. 2003;14:1889–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsuchiya N, Satoh S, Tada H, et al. Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplantation. 2004;78:1182–7.PubMedCrossRefGoogle Scholar
  15. 15.
    MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant. 2004;4:914–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Bekersky I, Dressler D, Mekki Q. Effect of time of meal consumption on bioavailability of a single oral 5 mg tacrolimus dose. J Clin Pharmacol. 2001;41:289–97.PubMedCrossRefGoogle Scholar
  17. 17.
    Kimikawa M, Kamoya K, Toma H, Teraoka S. Effective oral administration of tacrolimus in renal transplant recipients. Clin Transplant. 2001;15:324–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sofue T, Inui M, Kiyomoto H, et al. Pre-existing arteriosclerotic intimal thickening in living-donor kidneys reflects allograft function. Am J Nephrol. 2012;36:127–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Jaeger JQ, Mehta RL. Assessment of dry weight in hemodialysis: an overview. J Am Soc Nephrol. 1999;10:392–403.PubMedGoogle Scholar
  20. 20.
    Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753–60.PubMedCrossRefGoogle Scholar
  21. 21.
    Rudant E, Bezie Y, Bonhomme-Faivre L, et al. Study of the correlation between MEIA and ELISA methods for FK 506 determination in liver transplant recipients. J Clin Pharm Ther. 1997;22:135–40.PubMedCrossRefGoogle Scholar
  22. 22.
    Macphee IA, Fredericks S, Mohamed M, et al. Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. Transplantation. 2005;79:499–502.PubMedCrossRefGoogle Scholar
  23. 23.
    Iwasaki K, Shiraga T, Nagase K, et al. Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos. 1993;21:971–7.PubMedGoogle Scholar
  24. 24.
    Chen YL, Hirabayashi H, Akhtar S, Pelzer M, Kobayashi M. Simultaneous determination of three isomeric metabolites of tacrolimus (FK506) in human whole blood and plasma using high performance liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;830:330–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Shimomura M, Masuda S, Saito H, et al. Roles of the jejunum and ileum in the first-pass effect as absorptive barriers for orally administered tacrolimus. J Surg Res. 2002;103:215–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Tamura S, Tokunaga Y, Ibuki R, Amidon GL, Sezaki H, Yamashita S. The site-specific transport and metabolism of tacrolimus in rat small intestine. J Pharmacol Exp Ther. 2003;306:310–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753–61.PubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2012

Authors and Affiliations

  • Tadashi Sofue
    • 1
  • Masashi Inui
    • 2
  • Hideyasu Kiyomoto
    • 3
  • Kumiko Moriwaki
    • 1
  • Taiga Hara
    • 1
  • Kazunori Yamaguchi
    • 4
  • Noriyasu Fukuoka
    • 4
  • Kazuko Banno
    • 5
  • Akira Nishiyama
    • 6
  • Yoshiyuki Kakehi
    • 2
  • Masakazu Kohno
    • 1
  1. 1.Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Faculty of MedicineKagawa UniversityKagawaJapan
  2. 2.Department of Urology, Faculty of MedicineKagawa UniversityKagawaJapan
  3. 3.Division of Nephrology, Endocrinology and Vascular Medicine, Department of MedicineTohoku University Graduate School of MedicineSendaiJapan
  4. 4.Department of PharmacyKagawa University HospitalKagawaJapan
  5. 5.Shiga Pharmaceutical Association Proof CenterKusatsuJapan
  6. 6.Department of Pharmacology, Faculty of MedicineKagawa UniversityKagawaJapan

Personalised recommendations